Overview of clinical and molecular aspects involved in the development of symptomatic infection and end-organ disease caused by cytomegalovirus in pediatric patients

Cytomegalovirus Infections: Risk Factors, Causes and Management

Volumn , Issue , 2012, Pages 293-324

  José, Arellano Galindo ^a   Jesús, Casasola Flores ^a   Dina, Villanueva García ^a   Margarita, Nava Frías ^a   Norma, Velázquez Guadarrama ^a   Elva, Jiménez Hernández ^b   Rommel, Chacón Salinas ^c   Abel, Bello González ^a   Gabriel, Uribe Gutiérrez ^a   Javier, González Ramírez ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892921804     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (172)

1. Burbelo, P. D. Issa, A. T. Ching, K. H. Exner, M. W. Drew, L. Alter, et al. Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virol. J., 2009;1(6):45-3.
2. Soo, K. C. Congenital and perinatal cytomegalovirus infection. Korean J. Pediatr., 2010;53(1):14-20.
3. Crough, T. Khanna, R. Immunobiology of Human Cytomegalovirus: from Bench to Bedside. Clin. Microbiol. Rev., 2009;22(1):76-98.
4. Kawai, T., Akira, S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity. Immunity, 2011 27;34(5):637-50.
5. Taylor, R. T., Bresnahan, W. A. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J. Virol., 2005;79(6):3873-77.
6. Taylor, R. T., Bresnahan, W. A. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J. Virol., 2006;80(21):10763-71.
7. Chang, W. L., Barry, P. A., Szubin, R., Wang, D., Baumgarth, N. Human cytomegalo-virus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology, 2009;390(2):330-37.
8. Isaacs, A., Lindenmann, J. Virus interference I. The interferon. Proc. R. Soc. Lond. B Biol. Sci., 1957;147(927):258-67.
9. Der, S. D., Zhou, A., Williams, B. R., Silverman, R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U S A, 1998;95(26):15623-28.
10. Sadler, A. J., Williams, B. R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol., 2008;8(7):559-68.
11. Miller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W., et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med., 1998;187(5):675-83.
12. Miller, D. M., Zhang, Y., Rahill, B. M., Waldman, W. J., Sedmak, D. D. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol., 1999;162(10):6107-13.
13. Le, V. T., Trilling, M., Wilborn, M., Hengel, H., Zimmermann, A. Human cytomegalo-virus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol., 2008;89(Pt 10):2416-26.
14. Paulus, C., Krauss, S., Nevels, M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. U S A, 2006;103(10):3840-45.
15. Hakki, M., Geballe, A. P. Double-stranded RNA binding by human cytomegalovirus pTRS1. J. Virol., 2005;79(12):7311-18.
16. Meyers, J. D., McGuffin, R. W., Neiman, P. E., Singer, Jn. W., Thomas, E. D. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J. Infect. Dis., 1980;141(5):555-62.
17. Biron, C. A., Byron, K. S., Sullivan, J. L. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl. J. Med., 1989;320(26):1731-35.
18. Venema, H., Van den Berg, A. P., Van Zanten, C., Van Son, W. J., Van der Giessen, M., The TH. Natural killer cell responses in renal transplant patients with cytomegalo-virus infection. J. Med. Virol., 1994;42(2):188-92.
19. Cheent, K., Khakoo, S. I. Natural killer cells: integrating diversity with function. Immunology, 2009;126(4):449-57.
20. Lee, S. H., Miyagi, T., Biron, C. A. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol., 2007;28(6):252-9.
21. Beck, S., Barrell, B. G. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature, 1988;(6153):269-72.
22. Browne, H., Smith, G., Beck, S., Minson, T. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature, 1990;347(6295):770-72.
23. Reyburn, H. T., Mandelboim, O., Vales-Gomez, M., Davis, D. M., Pazmany, L., Strominger, J. L. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature, 1997;386(6624):514-17.
24. Chapman, T. L., Heikeman, A. P., Bjorkman, P. J. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity, 1999;11(5):603-13.
25. Dunn, C., Chalupny, N. J., Sutherland, C. L., Dosch, S., Sivakumar, P. V., Johnson, D. C., et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med., 2003;197(11):1427-39
26. Chalupny, N. J., Rein-Weston, A., Dosch, S., Cosman, D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun., 2006;346(1):175-81.
27. Nachmani, D., Lankry, D., Wolf, D. G., Mandelboim, O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat. Immunol., 2010;11(9):806-13.
28. Tomasec, P., Braud, V. M., Rickards, C., Powell, M. B., McSharry, B. P., Gadola, S., et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science, 2000;287(5455):1031.
29. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immuno., 2002;20:621-67.
30. Halary, F., Amara, A., Lortat-Jacob, H., Messerle, M., Delaunay, T., Houles, C., et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity, 2002;17(5):653-64.
31. Raftery, M. J., Schwab, M., Eibert, S. M., Samstag, Y., Walczak, H., Schonrich, G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity, 2001;15(6):997-1009.
32. Moutaftsi, M., Mehl, A. M., Borysiewicz, L. K., Tabi, Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood, 2002;99(8):2913-21.
33. Vyas, J. M., Van der Veen, A. G., Ploegh, H. L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol., 2008;8(8):607-18.
34. Gilbert, M. J., Riddell, S. R., Plachter, B., Greenberg, P. D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature, 1996;383(6602):720-22.
35. Wiertz, E. J., Tortorella, D., Bogyo, M. Y. J, Mothes, W., Jones, T. R., et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature, 1996;384(6608):432-38.
36. Wiertz, E. J., Jones, T. R., Sun, L., Bogyo, M., Geuze, H. J., Ploegh, H. L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell, 1996;84(5):769-79.
37. Jones, T. R., Wiertz, E. J., Sun, L., Fish, K. N., Nelson, J. A., Ploegh, H. L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. U S A, 1996;93(21):11327-33.
38. Park, B., Kim, Y., Shin, J., Lee, S., Cho, K., Fruh, K., et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity, 2004;20(1):71-85.
39. Furman, M. H., Dey, N., Tortorella, D., Ploegh, H. L. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J. Virol., 2002;76(22):11753-56.
40. Ahn, K., Gruhler, A., Galocha, B., Jones, T. R., Wiertz, E. J., Ploegh, H. L, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity, 1997;6(5):613-21.
41. Hegde, N. R., Tomazin, R. A., Wisner, T. W., Dunn, C., Boname, J. M., Lewinsohn, D. M., et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J. Virol., 2002;76(21):10929-41.
42. Tomazin, R., Boname, J., Hegde, N. R., Lewinsohn, D. M., Altschuler, Y., Jones, T. R., et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat. Med., 1999;5(9):1039-43.
43. Odeberg, J., Plachter, B., Branden, L., Soderberg-Naucler, C. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood, 2003;101(12):4870-77.
44. McGeoch, D. J., Rixon, F. J., Davison, A. J. Topics in herpesvirus genomics and evolution. Virus Res., 2006;117(1):90-104.
45. Shailendra, K., Shailja, S., Rakhi, S., Arvinda, S., Ankur, G., Madhavan, P. N. Emerging Trends, Challenges and Prospects in Antiviral Therapeutics and Drug Development for Infectious Diseases. E. J.Bio., 2010;6(2): 26-31.
46. Rivera, E., Tuset, M., Martín, M., Del Cacho, E.Characteristics of antiretroviral drugs.Enferm. Infecc. Microbiol. Clin., 2011;29(5):362-391.
47. Surya, K,. Anand, K. Maurya, Kushwaha R., Vijaya, L., Rajendra, P. Multidrug resistant tuberculosis: An iatrogenic problem. BioScience Trends, 2010; 4(2):48-55.
48. Fabien, Z. Definitions de la resistance aux antiviraux analogues dans le traitment de ĺhepatite Chronique B. Gastroenterol. Clin. Biol., 2006;30:3S9-2S11.
49. Sharla, M., Luck, S., Griffiths, P., Cotton, M. Antiviral Therapy of CMV Disease in Children. Hot topics in infection and immunity in children vii. Adv. Med. Exp. Biol., 2011;697:243-260.
50. Mercorelli, B., Sinigalia, E., Loregian, L., Palù, G. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol., 2008;18(3):177-210.
51. De Clercq, E. Antivirals and antiviral strategies. Nat. Rev. Microbiol., 2004;2(9):704-20.
52. Lischka, P., Hewlett, G., Wunberg, T., Baumeister, J., Paulsen, D., Goldner, G., Ruebsamen-Schaeff, H., Zimmermann, H. In vitro and in vivo Activities of the Novel Anticytomegalovirus Compound AIC246. Antimicrob Agents Chemother., 2010;54(3):1290-1297.
53. Tchesnokov, E., Obikhod, A., Schinazi, R., Gothe, M. Engineering of a Chimeric RB69 DNA Polymerase Sensitive to Drugs Targeting the Cytomegalovirus Enzyme. J. Biol. Chem., 2009;284(39):26439-46.
54. Madi, N., Widad, A., Pacsa, A. Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?. Advances in Virology, vol. 2011, Article ID 260561, 6 pages, 2011. doi:10.1155/2011/260561.
55. Boivin, G., Goyette, N., Rollag, H., Jardine, A., Pescovitz, M., Asberg, A., Ives, J., Hartmann, A., Humar, A. Cytomegalovirus resistance in solid transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir. Ther., 2009;14:697-704.
56. Michel, D., Höhn, S., Haller, T., Jun, D., Mertens, T. Aciclovir selects forAntimicrob Agents Chemother. 2010;54(3):1290-1297. ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J. Med. Virol., 2001;65(1):70-6.
57. Strasfeld, L., Chou, S. Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infect. Dis. Clin. N Am., 2010;24:809-833.
58. Kotton, C. Management of cytomegalovirus infection in solid organ transplantation. Nat. Rev. Nephrol., 2010;6:711-721.
59. Lurain, N. S., Chou, S. Antiviral Drug Resistance of Human Cytomegalovirus. Clin. Microbiol. Rev., 2010;23(4):689-712.
60. Arellano-Galindo, J., Vázquez-Meraz, E., Jimenez-Hernández, E., Velazquez-Guadarrama, N., Mikeler, E., Hamprecht, K., et al. The role of cytomegalovirus infection and disease in pediatric bone marrow transplant recipients in Mexico City in the context of viral drug resistance. Pediatr.Transplantation, 2011;15:103-11.
61. Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C., Drew, W. L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis., 2003;188(1):32-9
62. Drew, W., Stempien, M., Andrews, J., Shadman, A., Tan, S., Miner, R., et al. Cytomegalovirus (CMV) Resistance in Patients with CMV Retinitis and AIDS Treated with Oral or Intravenous Ganciclovir. J. Infect. Dis., 1999;179(6):1352-55.
63. Limaye, A. P., Corey, L., Koelle, D. M., Davis, C. L., Boeck, M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000;356:645-49.
64. Isada, C. M., Yen-Lieberman, B., Lurain, N. S., Schilz, R., Kohn, D., Longworth, D. L., et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl. Infect. Dis., 2002;4(4):189-94.
65. Boivin, G., Goyette, N., Gilbert, C., Humar, A., Covington, E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis., 2005;7(3-4):166-70.
66. Dal Monte, P., Pignatelli, S., Rossini, G., Landini, M. Genomic Variants Among Human Cytomegalovirus (HCMV) Clinical Isolates: The Glycoprotein N (gN) Paradigm. Human Immunol., 2004; 65(5):387-94.
67. Chandler, S. H., Handsfield, H. H., Mcdougall, J. K.: Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J. Infect. Dis., 1987;155(4):655-60.
68. Meyer-König, U., Ebert, K., Schrage, B., Pollak, S., Hufert, F. T. Simultaneous infection of healthy people with multiple human cytomegalovirus strains. Lancet,1998;352(9136):1280-81.
69. Picone, O., Costa, J. M., Leruez-Ville, M., Ernault, P., Olivi, M., Ville, Y. Cytomegalovirus (CMV) glycoprotein B genotype and CMV DNA load in the amniotic fluid of infected fetuses. Prenat. Diag. 2004;24(12):1001-6.
70. Chou, S. W., Dennison, K. M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis., 1991;163(6):1229-34.
71. Puchhammer-Stöckl, E., Görzer, I. Human Cytomegalovirus An enormous variety of strains and Their Possible Clinical Significance in the Human Host. Future Virology, 2011;6(2):259-71.
72. Tarrago, D., Quereda, C., Tenorio, A. Different Cytomegalovirus Glycoprotein B Genotype Distribution in Serum and Cerebrospinal Fluid Specimens Determined by a Novel Multiplex Nested PCR. J. Clin. Microbiol., 2003;41:2872-77.
73. Shepp, D. H., Match, M. E., Ashraf, A. B., Lipson, S. M., Millan, C., Pergolizzi, R. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. J. Infect. Dis., 1996;174:184-87.
74. Pang, X., Humar, A., Preiksaitis, J. K. Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J. Clin. Microbiol., 2008;46(12):4004-10.
75. Peek, R., Verbraak, F., Bruinenberg, M., Van der Lelij, A., Van den Horn, G., Kijlstra, A. Cytomegalovirus glycoprotein B genotyping in ocular fluids and blood of AIDS patients with cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci., 1998;39(7):1183-87.
76. Woo, P. C., Lo, C. Y., Lo, S. K., Siau, H., Peiris, J. S., Wong, S. S., Luk, W. K., Chan, T. M., Lim, W. W., Yuen, K. Y. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease. Clin. Diagn. Lab. Immunol., 1997;4(5): 515-518.
77. Hong, J., Xiuxia, W., Shuomin, L. Human Cytomegalovirus Glycoprotein B Genotype Correlates with Different Symptoms of Infected Infants. Intervirology, 2007;50:219-223.
78. Barbi, M., Binda, S., Caroppo, S., Primache, V., Didò, P., Guidotti, P., et al. CMV gB genotypes and outcome of vertical transmission: study on dried blood spots of congenitally infected babies. J. Clin. Virol., 2001;21(1):75-9.
79. Pignatelli, S., Rossini, G., Dal Monte, P., Gatto, M. R., Landini, M. P. Human cytomegalovirus glycoprotein N (gN) genotypesin AIDS patients. AIDS, 2003;17:761-63.
80. Pignatelli, S., Dal Monte, P., Rossini, G., Chou, S., Gojobori, T., Hanada K. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identificationof a novel subgroup, geographical distribution and evidence of positive selective pressure. J. Gen. Virol., 2003;84: 647-655.
81. Pignatelli, S., Lazzarotto, T., Gatto, M., Dal Monte, P., Landini, M., Faldella, G., et al. Cytomegalovirus gN Genotypes Distribution among Congenitally Infected Newborns and Their Relationship with Symptoms at Birth and Sequelae. Clin. Infect. Dis., 2010; 51 (1): 33-41.
82. González-Ramírez, J. Uribe-Gutiérrez, G., Jiménez-Hernandez, E. Velázquez-Guadarrama, N., Bello-González, A., Vazquez-Meraz, E., et al. Cytomegalovirus gB Genotype Distribution in Mexican Children Undergoing Allogeneic Bone Marrow Transplantation. 2011. Intervirology, (doi:10.1159/000328665).
83. Cicin-Sain, L., Podlech, J., Messerle, M., Reddehase, M. J., Koszinowski U. H. Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J. Virol., 2005;79(15):9492-9502.
84. Madi, N., Al-Nakib, W., Pacsa, A., Saeed, T. Cytomegalovirus Genotypes gB1 and gH1 Are the Most Predominant Genotypes among Renal Transplant Recipients in Kuwait. Transplant. Proc., 2011;43(5):1634-37.
85. Milan, A., Sampaio, A. M., Guardia, A. C., Pavan, C. R., Andrade, P. D., Bonon, S. H., et al. Monitoring and detection of cytomegalovirus in liver transplant recipients. Transplant. Proc., 2011;43(4):1360-61.
86. Costa, C., Astegiano, S., Terlizzi, M. E., Sidoti, F., Curtoni, A., Solidoro, P., et al. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant. Proc., 2011;43(4):1159-61.
87. Batista, M. V., Pierrotti, L. C., Abdala, E., Clemente, W. T., Girão, E. S., Rosa, D. R. Et al. Endemic and opportunistic infections in Brazilian solid organ transplant recipients. Trop. Med. Int. Health, 2011. (doi: 10.1111/j.1365-3156.2011.02816.x.).
88. Castro-Ferreira, I., Carvalho, C., Coentrão, L., Gaião, S., Bustorff, M., Santos, J., et al. Early-onset of disseminated cryptococcal infection in two renal transplant recipients. Clin. Nephrol., 2011;75(6):542-46.
89. Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood, 2002; 100: 4358-66.
90. Yager, E. J., Szaba, F. M., Kummer, L. W., Lanzer, K. G., Burkum, C. E., Smiley, S. T., et al. Herpesvirus-Induced Protection Against Bacterial Infection Is Transient. Viral. Immunology, 2009; 22: 67-71.
91. Miller-Kittrell, M., Sparer, T. E. Feeling manipulated: Cytomegalovirus immune manipulation Virol. J., 2009; 6:4-24.
92. Loewendorf, A., Benedict, C. A.. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J. Intern. Med., 2010; 267(5): 483-501.
93. Zhu, H., Shen, Y., Shenk, T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol., 1995;69:7960-70.
94. Liu, R., Moroi, M., Yamamoto, M., Kubota, T., Ono, T., Futnatsu, A., et al. Presence and Severity of Chlamydia pneumoniae and Cytomegalovirus Infection in Coronary Plaques Are Associated With Acute Coronary Syndromes. Int. Heart J., 2006;4:511-19.
95. Barton, E. S., Douglas, W. White, D. W., Cathelyn, J. S., Brett-McClellan, K. A., Engle, M., et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature, 2007. 447: 326-330.
96. Patel, R., Paya, C. Infecgtions in Solid-Organ Transpant Recipents. Clin. Microbiol. Rev., 1997;10(1):86-124.
97. Preiksoits, J., Brennan, D., Fishman, J., Allen, D., Canadian Society of Transplatation Consensus Workshop on Citomegalovirus Management in Solid organ Trasplantation Final Report. Am. J. Transplant., 2005;5(2):218-27.
98. Haday, K., Wenderli, W., Deffernez, C., Martin, P., Mentha, G., Binet, Monitoring of Cytomegalovirus Infection in Solid-Organ Transplant Recipients by an Ultrasensitive Plasma PCR Assay. J. Clin. Microbiol., 2003;41:3757-64
99. Kotton, C. N. Management of cytomegalovirus infection in solid organ transplantation. Nat. Rev. Nephrol., 2010; 6:711-21.
100. Nichols, W. G., Corey, L., Gooley, T., Davis, C., Boeckh, M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV) seronegativo recipients of stem cell transplantation from seropositive donors evidence for indirect effects of primary CMV infection. J. Infect. Dis., 2002;185:273-82.
101. Boeckh, M., Leisenring, W., Riddell, S. R., Bowden, R. A., Huang, M. L., Myerson, D., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood, 2003;101:407-14.
102. Zaia, J. H. Cytomegalovirus Infection. In. Forman SJ, Blume KG, Thomas ED. Bone Marrow Transplantation. Boston MA, Blackwell 1994;28:376-403.
103. Ljungman, P., Griffiths, P., Paya, C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis., 2002;34:1094-97.
104. Zaia, J. A. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant., 2002;29:633-38.
105. Castagnola, E., Cappelli, B., Erba, D., Rabagliati, A., Lanino, E., Dini, G. Cytomegalo-virus Infection After Bone Marrow Trasplantation in Children. Human Inmunol., 2004;65:416-22.
106. Osarogiagbon, R. U., Defor, T. E., Weisdorf, M. A., Erice, A., Wisdorf, D. J. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol. Blood Marrow Transplant., 2000;6:280-88.
107. George, B., Pati, N., Gilroy, N., Ratnamohan, M., Huang, G., Kerridge, I. et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl. Infect. Dis., 2010;12:322-29.
108. Verdeguer, A., Heredia, C. D., González, M., Martínez, A. M., Fernández-Navarro, J. M., Pérez-Hurtado, J. M. et al. Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation a 3-year GETMON experience. Bone Marrow Transplant., 2011;46:119-24.
109. Pietersma, F. L., Van Dorp, S., Minnema, M. C., Kuball, J., Meijer, E., Schuurman, R., et al. Influence of Donor Cytomegalovirus (CMV) Status on Severity of Viral Reactivation After Allogeneic Stem Cell Transplantation in CMV-Seropositive Recipients. Clinical Infect. Dis., 2011;52:144-48.
110. Lin, S. T., Zahrieh, D., Weller, E., Alyea, P. E., Antin, H. J., Soiffer, J. R. et al. Risk factors for cytomegalovirus reactivation after CD6+ T-Cell-Depleted allogeneic bone marrow transplantation. Transplantation, 2002;74:49-54.
111. Tan, B. H., Chlebicka, N. L., Hong, Low, G. J., Chong, T. Y. R., Chan, K. P., Goh, Y. T. et al. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review. Transpl. Infect. Dis., 2008;10:325-32.
112. Ozdemir, E., Saliba, R. M., Champlin, R. E., Couriel, D. R., Giralt, S. A., De Lima, M., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transpl., 2007;40:125-136.
113. Behrendt, C. E., Rosenthal, J., Bolotin, E., Nakamura, R., Zaia, J., Forman, S. J. Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy. Biol. Blood Marrow Transplant., 2009;15:54-60.
114. Reusser, P., Fisher, L. D., Buckner, C. D., Thomas, E. D., Meyer, J. D. Cytomegalo-virus infection, after autologous bone marrow transplantation: ocurrence of cytomegalovirus disease and effect on engranftment. Blood, 1990;75:1888-94.
115. Konoplev, S., Champlin, R. E., Giralt, S., Ueno, N. T., Khouri, I., Raad, I. Et al, Cytomegalovirus pneumonia in adults autologous blood and marrow transplant recipients. Bone Marrow Transplant., 2001;27:877-81.
116. Ljungman, P., Biron, P., Bosi, A., Cahn, J. Y., Goldstone, A. H., Gorin, N. C., et al Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant., 1994;13:209-12.
117. Holmberg, L. A., Boeckh, M., Hooper, H., Leisenring, W., Rowley, S., Heimfeld, S., et al. Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation. Blood, 1999;94:4029-35.
118. Barker, J. N., Wargner, J. E.. Umbilical -cord blood transplantation for the treatment of cancer. Nat. Rev. Cancer, 2003;3:526-32
119. Rocha, V., Kabbara, N., Ionescu, I., Ruggeri, A., Purtill, D. and Gluckman. Pediatric related and unrelated cord blood transplantation. Bone Marrow Transplant., 2009;44:653-59.
120. Albano, M. S., Taylor, P., Pass, R. F., Scaradavou, A., Ciubotariu, R., Carrier, C., et al. Umbilical cord blood transplantation and cytomegalovirus posttransplantation infection and donor screening. Blood, 2006;108:4275-82.
121. Theiler, R. N., Caliendo, A. M., Pargman, S., Raynor, B. D., Berga, S., McPheeters, M., et al. Umbilical cord blood screening for cytomegalovirus DNA by quantitative PCR. J. Clin. Virol., 2006;37:313-16.
122. Takami, A., Mochizuki, K., Asakura, H., Yamasaki, H., Okumura, H., Nakao, S. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica, 2005;90:1290-92.
123. Matsumura, T., Narimatsu, H., Kami, M., Yuji, K., Kusumi, E., Hori, A., et al, Cytomegalovirus Infection following umbilical, cord blood transplantation using reduced intensity conditioning regimens for adults patients. Biol. Blood Marrow Transplant., 2007;13:577-83.
124. Martin, P. J., Komanduri, K. V., St. John, L. S., et al Delayed immune reconstitution after cord blood transplantation is caracterized by impaird thymopoiesis and late memory T-cell skewing. Blood, 2007;110:4543-51.
125. Szabolcs, P., Niedzwiecki, D. Inmune reconstitutión after unrelated cord blood transplantation. Cytotherapy, 2007;9:111-22.
126. Beck, C. J., Wagner, E. J., DeFor, T. E., Brunstein, C. G., Schleiss, R. M., Young, J. et al. Impact of Cytomegalovirus (CMV) reactivation after umbilical cord blood transaplantation. Biol. Blood Marrow Transplant., 2010;16:215-22.
127. Ruggeri, A., Peffault, De Latour, R., Carmagnat, M., Clave, E., Douay, C., Larghero, J. et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl. Infect. Dis., 2011. doi: 10.1111/j.1399-3062.2011.00632.x.
128. Nakamae, H., Kirby, K., Sandmaier, B., Norasetthada, L., Maloney, D., Maris, M., Effect of conditioning regimen intensity CMV infection in allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2009;15:694-703.
129. Peres, M. B., Costa, R. C., Andrade, D., Bonon, H. A., Aluquerque, M., Oliveira, C. et al. Surveillance of active human cytomegalovirus infection in hematopoietic ítem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect. Dis., 2010;10:147-54.
130. Mc Sweeney, P. A., Neiderwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001;97:3390-3400.
131. Martino, R., Caballero, M. D., Canals, C., San Miguel, J., Sierra, J., Rovira, M., et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation. Bone Marrow Transplant., 2001;28:341-47.
132. Mohty, M., Jacot, W., Faucher, C., Bay, J. O., Zandotti, C., Collet, L., et al. Infectious complications following allogeneic HLA-identico sibling transplantation with antithymocyte globulin based reduced intensity preparative regimen. Leukemia, 2003;17:2168-71.
133. Buyck, H. C., Prentice, H. G. F., Griffiths, P. D. and Emery, V. C. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant., 2010;45:1212-19.
134. Piñana, J. L., Martino, R., Barba, P., Margall, N., Roig, M. C., Valcárcel, D., Sierra, J., Rabella, N. Cytomegalovirus infection and disease alter reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. Bone Marrow transplant., 2010;45:534-42.
135. Zaia, J., Baden, L., Boeckh, M. J., Chakrabarti, S., Einsele, H., Ljungman, P., McDonald, G. B. and Hirsch, H.Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant., 2009;44:471-82.
136. George, B., Kerridge, I., Gilory, N., Huan, G., Hertzberg, M., Gottlieb, D. et al. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. Bone Marrow Transplant., 2010;45:849-55.
137. Kalpoe, J. S., Van der Heiden, P. L. S., Vaessen, N., Claas, E. C. J., Barge, R. M. Kroes, A. C. M. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant., 2007;40:137-43.
138. Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M. et al. Early CMV virema is associated with impared viral control following nonmyeloablative hematopoietic cell transplantation with total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol. Blood Marrow Transplant., 2011;17:693-702.
139. Meyers, J. D., Flournoy, N., Thomas, E. D. Risk factors of cytomegalovirus pneumonia after human marrow transplantation. J. Infect. Dis., 1986;153:478-88.
140. Auber, G., Hassan-Walker, A. F., Madrigal, J. A., Emery, V. C., Morte, C., Grace, S. et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J. Infect. Dis., 2001;184:955-63.
141. Hakki, M., Riddell, S. R., Storek, J., Carter, R. A., Stevens-Ayers, T., Sudour, P., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug, therapy, and subclinical reactivation. Blood, 2003;102:3060-67.
142. Guérin, V., Dalle, J. H., Pédron, B., Ouachée-Chardin, M., Yakouben, K., Baruchel, A., Sterkers, G. Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplant., 2010;45:442-49.
143. Broimans, R. A., Boyce, C. S., Popma, J., Broyles, A., Gratama, J. W., Southwick, P. C., et al. Analytical performance of a standardized single-platform MHC tetramer assay the identification and enumeration of CMV-specific CD8+ T lymphocites. Cytometry A, 2008;73:992-1000.
144. Ratko, T. A., Cummings, J. P., Oberman, H. A., Crookston, K. P., De Christopher, P. J., Eastlund, D. T., et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion, 2001;41:1310-19.
145. Emery, V. C., Cope, A. V., Sabin, C. A., Burroughs, A. K., Rolles, K., Lazzarotto, T. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. J. Infect, Dis., 2000;182(6):1610-15.
146. Cope, A. V., Sabin, C., Burroughs, A., Rolles, K., Griffiths, P. D., Emery, V. C. Inter-relationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis., 1997;176:1484-90.
147. Bowden, R. A., Slitcher, J. S., Sayers, M., Weisdorf, D., Cays, M., Schoch, G. et al. A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant. Blood, 1995;86:3598-3603.
148. Jaskula, E., Dlubek, D., Sedzimirska, M., Duda, D., Tarnowska, A., Lange, A. Reactivations of Cytomegalovirus, Human Herpes Virus 6, and Epstein-Barr Virus Differ with Respect to Risk Factors and Clinical Outcome after hematopoietic stem cell transplantation. Transplant. Proc. 2010;42:3273-76.
149. Fabio, M., Lorenza, P. Cytomegalovirus infection: the state of the art. J. Chemother., 2007;l:46-8.
150. Oriol, C., Guillaume, B., Yves, V., Leonard, E. W., Francesc, B. et al. Guidelines on CMV congenital infection. Perinatal Infections Working Group. J. Perinat. Med., 2009;37(5):433-45.
151. Aileen, K., Michael, J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol., 2007; 17: 253-276.
152. Stuart, P., Giovanni, N., Lenore, P. Recent Advances in the Prevention and Treatment of Congenital Cytomegalovirus Infections. Semin. Perinatol., 2007;31:10-18.
153. Vaudry, W., Rosychuk, R. J., Lee, B. E., Cheung, P. Y., Pang, X. L., Preiksaitis, J. K. Congenital cytomegalovirus infection in high risk Canadian infants: Report of a pilot screening study. Can. J. Infect. Dis. Med. Microbiol., 2010;21(1):e12-e19.
154. Di Nardo, W., Cattani, P., Lopizzo, T., Cpantore, I., Marchese, M. R., Marchetti, S., Scorpecci, A., Giannantonio, S., Parrilla, C., Cianfrone, F., Fadda, G., Paludetti, G. Multiple viral genome search in endolabyrinthic fluids of profoundly deaf patients: possible cytomegalovirus intracochlear reactivation. Audiol. Neurootol., 2009;14 (5):290-95.
155. Fortunato, E. A., Dell'Aquila, M., Spector, D. Specific chromosome 1 breaks induced by human cytomegalovirus. Proc. Natl. Acad. Sci., USA. 2000;97:853-858.
156. Nystad, M., Fagerheim, T., Brox,V.,Fortunato, E., Nilssen, O. Human cytomegalovirus (HCMV) and hearing impairment: Infection of fibroblast cells with HCMV induces chromosome breaks at 1q23.3, between loci DFNA7 and DFNA49-Both involved in dominantly inherited, sensorineural, hearing impairment. Mutat. Res., 2000;637:1-2.
157. De Biasi, R. L., Kleinschmidt-DeMasters, B. K., Richardson-Burns, S., Tyler, K. L. Central nervous system apoptosis in human herpes simplex virus and cytomegalovirus encephalitis. J. Infect. Dis., 2002. 186:1547-1557.
158. Cheeran,M. C., Hu, S., Ni, H. T., Sheng, W., Palmquist, J. M., Peterson, P. K., Lokens-gard, J. R. Neural precursor cell susceptibility to human cytomegalovirus diverges along glial or neuronal differentiation pathways. J. Neurosci. Res., 2005. 82:839-850.
159. Odeberg, J., Wolmer, N., Falci, S., Westgren, M., Sundtrom, E., Seiger, A., Soderberg-Naucler.,C. Late human cytomegalovirus (HCMV) proteins inhibit differentiation of human neural precursor cells into astrocytes. J. Neurosci. Res., 2007.85:583-593.
160. Mutnal, B., Cheeran, C., Hu, S., Lokensgard, J. R. Murine cytomegalovirus infection of neural stem cells alters neurogenesis in the developing brain. PLoS. One, 2011;6(1):e16211.
161. Webster, A., Lee, C. A. Cook, D. G. et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet, 1989; 2: 63-66.
162. Drew, W. L. Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis., 1992; 14: 608-615.
163. Gallant, J. E., Moore, R. D., Richman, D. D., Keruly, J., Chaisson, R. E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J. Infect. Dis., 1992;166: 1223-1227.
164. Kestelyn, P. G., Cunningham, E. T. HIV / AIDS and blindness. Bull WHO, 2001; 79: 208-213.
165. Kedhar, S. R., Jabs, D. A. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes, 2007;14(3):66-71.
166. Detels, R., Tarwater, P., Phair, J. P., Margolick, J., Riddler, S. A., Munoz, A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS, 2001; 15: 347-355.
167. Clayton, F., Clayton, C. H. "Gastrointestinal pathology in HIV-infected patients. Gastroenterol. Clin. North. Am., 1997;26 (2):191-240.
168. Anduze-Faris, B. M., Fillet, A. M., Gozlan, J., Lancar, R., et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.AIDS, 2000;14(5):517-24.
169. Van der Meer, J. T., Drew, W. L., Bowden, R. A., et al. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral. Res., 1996;32(3):119-40.
170. Robain, M., Carre, N., Dussaix, E., Salmon-Ceron, D., Meyer, L. Incidence and sexual risk factors of cytomegalovirus seroconversion in HIV-infected subjects. The SEROCO study group. Sex. Transm. Dis., 1998;25(9):476-480.
171. Adler, S. P., Finney, J. W., Manganello, A. M., Best, A. M. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J. Pediatr., 2004;145(4):485-491.
172. Nichols, W. G., Price, T. H., Gooley, T., Corey, L., Boeckh, M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 2003;101(10):4195-4200.